




# ENGOT Ov-15 Trial

## AGO-OVAR 17

### Study Design



#### Strata

- ◆ macroscopic residual tumor (yes vs no)
- ◆ FIGO Stage (IIB-IIIC vs IV)
- ◆ Study Group

Primary endpoint:

- ◆ PFS (non inferiority -> superiority)

Main question: treatment duration Bev



# ENGOT Ov-15 Trial

## AGO-OVAR 17



- ◆ Participating ENGOT Groups
  - AGO Study Group (Leading Group)
  - GINECO (France)
  - NSGO (Scandinavia)
  
- ◆ First Patient In = November 2011
- ◆ Last Patient In = 06. August 2013
  
- ◆ 927 Patients in total in 22 months
- ◆ NSGO = 37 Patients / GINECO = 126 Patients / AGO = 764 Patients



# ENGOT Ov-15 Trial AGO-OVAR 17

Recruitment 06.08.2013; n = 927

